These neurotransmitter-cognition results are in line with previous reports e.g., dopamine and serotonin have previously been shown to be important for cognitive processes (e.g., 109, 110, 111), VACHT dysfunction has been shown to be related to intellectual disabilities and Parkinson’s Disease, as well as to prefrontal cortex functioning (112,113), acute CB1 disruption results in a decline in verbal learning and working memory performance 114, and NMDA has been selected as a promising target for cognitive enhancement e.g., in dementia (115, 116). This evidence concerns the gene SLC18A3 and dementia.